Cargando…
Pneumococcal conjugate vaccines PREVenar13 and SynflorIX in sequence or alone in high-risk Indigenous infants (PREV-IX_COMBO): protocol of a randomised controlled trial
INTRODUCTION: Otitis media (OM) starts within weeks of birth in almost all Indigenous infants living in remote areas of the Northern Territory (NT). OM and associated hearing loss persist from infancy throughout childhood and often into adulthood. Educational and social opportunities are greatly com...
Autores principales: | Leach, Amanda Jane, Mulholland, Edward Kim, Santosham, Mathu, Torzillo, Paul John, Brown, Ngiare Joy, McIntyre, Peter, Smith-Vaughan, Heidi, Skull, Sue, Balloch, Anne, Andrews, Ross, Carapetis, Jonathan, McDonnell, Joseph, Krause, Vicki, Morris, Peter Stanley |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4298104/ https://www.ncbi.nlm.nih.gov/pubmed/25596202 http://dx.doi.org/10.1136/bmjopen-2014-007247 |
Ejemplares similares
-
Interchangeability, immunogenicity and safety of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (Synflorix) and 13-valent-PCV (Prevenar13) schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial
por: Leach, Amanda Jane, et al.
Publicado: (2021) -
Acridine form IX
por: Stephens, Peter W., et al.
Publicado: (2019) -
Genes IX /
por: Lewin, Benjamin
Publicado: (2008) -
Genes IX /
por: Lewin, Benjamin
Publicado: (2008) -
Hæmatology—IX
Publicado: (1910)